سعر سوربيستريت باودر 500 جم 2024

Calcium polystyrene sulfonate powder for oral or rectal suspension, 500 g container; Fresenius Kabi, imported by the Egyptian Group for Import and Export.

• Treatment of hyperkalaemia, particularly in patients with acute or chronic renal insufficiency, including patients on dialysis.AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)

• Common: hypercalcaemia, hypokalaemia, hypomagnesaemia, nausea, vomiting. Uncommon: constipation, diarrhoea, intestinal obstruction, gastric ulcers, colonic necrosis leading to perforation (sometimes fatal), anorexia. Rare: ileus from resin aggregation, faecal impaction after rectal use in children. Very rare: bronchitis/bronchopneumonia after inhalation of the resin.International label, same formulation · AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)

• Plasma potassium below 5 mmol/L; conditions associated with hypercalcaemia (e.g. hyperparathyroidism, multiple myeloma, sarcoidosis, metastatic carcinoma); hypersensitivity to the active substance or excipients.International label, same formulation · AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)
• Obstructive bowel disease, reduced gut motility, risk of colonic necrosis, concomitant sorbitol; oral use in neonates and any route in neonates with reduced gut motility.International label, same formulation · AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)

• Not sufficiently effective for hyperkalaemia above 6.5 mmol/L and/or with ECG changes; use emergency measures (bicarbonate, glucose-insulin) or dialysis instead.International label, same formulation · AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)
• Gastrointestinal stenosis, intestinal ischaemia, necrosis and perforation (some fatal) have been reported with polystyrene sulfonate alone or with sorbitol; patients should seek prompt care for severe abdominal pain, nausea, vomiting, distension or rectal bleeding; stop if clinically significant constipation occurs.International label, same formulation · AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)
• Possible severe hypokalaemia (care with digitalis), hypercalcaemia (especially with calcium-rich diet, calcium phosphate binders or vitamin D analogues) and hypomagnesaemia.International label, same formulation · AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)

• Sorbitol (oral or rectal)Concomitant use may cause colonic necrosis; contraindicated.AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)
• Other oral medicinesThe resin binds orally administered drugs and may reduce their absorption and efficacy; separate by at least 3 hours (6 hours in gastroparesis).AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)
• Non-absorbable cation-donating laxatives and antacids (magnesium hydroxide, aluminium hydroxide, calcium carbonate)Systemic alkalosis reported; aluminium hydroxide may cause intestinal obstruction; leave a time interval.AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)

• No or limited data in pregnant women and insufficient animal data; should not be used in pregnancy unless the clinical situation requires treatment with calcium polystyrene sulfonate.International label, same formulation · AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)
• Insufficient information on excretion into breast milk; should not be used during breastfeeding unless clearly necessary.International label, same formulation · AEMPS CIMA (Spanish Agency of Medicines and Medical Devices)

• Calcium polystyrene sulfonate: Releases calcium in the intestine and binds potassium, reducing potassium absorption and its metabolic availability; the resin is not absorbed and is excreted in the faeces.